Compare Acadia Healthcare Company Inc (ACHC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Summit Therapeutics Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.61 (market cap $2.94B), while Summit Therapeutics Inc trades at $15.74 (market cap $12.32B). The key difference: Summit Therapeutics Inc is far larger — about 4.2× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | SMMT | |
|---|---|---|
Market Cap | $2.94B | $12.32B |
Sector | Health | Health |
52-Week High | $31.92 | $29.32 |
52-Week Low | $11.68 | $13.05 |
Enterprise Value | $5.45B | $11.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
